Clinical Trial Update: Erlotinib and SBRT in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating erlotinib with SBRT for locally advanced or metastatic non-small cell lung cancer has completed; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2018-04-23